[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@investseekers Avatar @investseekers Investseekers

Investseekers posts on X about $nvo, stocks, novo, nvo the most. They currently have XXXXX followers and XXX posts still getting attention that total XXXXXX engagements in the last XX hours.

Engagements: XXXXXX #

Engagements Line Chart

Mentions: XX #

Mentions Line Chart

Followers: XXXXX #

Followers Line Chart

CreatorRank: XXXXXXX #

CreatorRank Line Chart

Social Influence

Social category influence stocks #5051 finance XXXXX% countries XXXX% currencies #1474 cryptocurrencies XXXX% travel destinations XXXX% technology brands XXXX% exchanges XXXX% fashion brands XXXX%

Social topic influence $nvo #10, stocks #2254, novo #183, nvo #10, denmark #413, target #1831, strong #2592, $lly #14, bank 5.33%, pill #138

Top accounts mentioned or mentioned by @woodywgxonfire @preseidentmusk @researchpulse1 @dividendtsar @misswolf72 @tonymacarroni91 @remington00 @seep2p @1mak_96 @europeandgi @vanhovepieter @stockmktnewz @firedupwealth @joecarlsonshow @sopcaja @janthecurious1 @greentully @dalioinvest @humlerun @markedsbrok

Top assets mentioned Novo-Nordisk (NVO) Eli Lilly and Company (LLY) TransDigm Group, Inc. (TDG) Alibaba Group (BABA) Bank of America (BAC) Hims & Hers Health, Inc. (HIMS) A O Smith Corp (AOS) Momo (MOMO) Royalty Pharma plc Class A Ordinary Shares (RPRX) Unifi Protocol DAO (UNFI) Morgan Stanley (MS) PoolTogether (POOL) IDEXX Laboratories, Inc. (IDXX) Microsoft Corp. (MSFT) JPMorgan Chase (JPM) JinPeng (JIN) Costco Wholesale Corporation (COST) Costco Hot Dog (COST)

Top Social Posts

Top posts by engagements in the last XX hours

"$AOS reports earnings next week. It may sound boring but as a leading maker of water heating and treatment solutions demand for its products is steady and recurring. With a 1015 year replacement cycle its revenue is largely insulated from economic swings. Read my full analysis here: #stocks #investing"
X Link 2025-10-25T15:56Z 4885 followers, XXX engagements

"At midday $NVO s Alzheimer trial disappointment flipped the C25 from green to red. The index which started the day in solid gains ended barely negative at 0.01%. Zealand Pharma led the index with +3.7% on no company-specific news. At the bottom were Novo Nordisk and Pandora Novo heavily impacted by the trial miss and Pandora down XXX% also without any stock-specific catalyst. #StocksToWatch #investing"
X Link 2025-11-24T19:05Z 4885 followers, 1057 engagements

"I added more $NVO today its still my second-largest position after Prosus. If the 3-day rule ends up applying to Novo Nordisk Ill probably be buying again tomorrow and Wednesday too. #StocksToWatch #investing"
X Link 2025-11-24T19:36Z 4886 followers, 5163 engagements

"$BABA reports earnings Tuesday and its my third-largest position after $NVO and Prosus. #Alibaba is a dominant force in China with an ecosystem that spans e-commerce cloud computing logistics and digital services. Taobao and Tmall lead online retail Alibaba Cloud is a major player and the company is doubling down on AI global expansion and new monetization tools. Why I own it: #StocksToWatch #investing"
X Link 2025-11-24T21:33Z 4885 followers, 1301 engagements

"$PROSY bought back 1069070 shares last week at an average price of XXXXX. Like clockwork they have repurchased shares every week since June 2022. It remains my largest position ahead of $NVO. #StocksToWatch #investing"
X Link 2025-11-25T21:08Z 4885 followers, 1012 engagements

"The Danish C25 index climbed XXXX% on Wednesday. The biggest gainer was $NVO closing up XXXX% followed by Zealand Pharma (+3.07%) and $GMAB (+2.50%). The weakest performer was Rockwool. Despite slightly beating expectations on both revenue and profit in its Q3 results the stock still fell XXXX% on the day. #StockMarket #investing"
X Link 2025-11-26T16:37Z 4886 followers, 1319 engagements

"The Danish C25 index ended up XXX% on Friday. rsted was the best-performing stock followed by $NVO. At the bottom of the index was Zealand Pharma which fell 1.8%. #stockmarkets #Denmark"
X Link 2025-11-28T19:29Z 4886 followers, 1370 engagements

"Jyske Bank just published fresh analysis on $NVO and the firm now sets a 12-month price target of XXX DKK. Their take: Novo has faced a tough year pressure from compounders rising competition guidance cuts pricing headwinds US policy risks and CagriSema data that didnt meet expectations. Investor sentiment remains fragile and rebuilding confidence will take time as Novo works to re-accelerate growth. But Jyske Bank still sees strong long-term potential: a solid pipeline industry-leading capacity and attractive (though lower than before) growth prospects. Potential catalysts: Wegovy pill"
X Link 2025-11-29T16:05Z 4881 followers, 9986 engagements

"$NVO is warning the EU about a loophole that could open the door to fake or unregulated versions of Ozempic and Wegovy. The company says new EU pharma rules may let some pharmacies compound their own weight-loss drugs at scale creating a Wild West of unauthorised medicines and boosting the risk of counterfeits entering legitimate channels. But Europes largest pharmacist group calls it a false alarm insisting the rules wouldnt allow mass production or stockpiling of GLP-1 copycats. EU lawmakers are still negotiating the legislation with a final deal expected in December. Link to article:"
X Link 2025-11-30T07:46Z 4881 followers, 5486 engagements

"I guess everyone here knows I own $NVO but with the Danish #StockMarket underperforming this year many other high-quality Danish companies are suddenly trading at much more attractive valuations. One of them is Coloplast and Im considering buying soon. Its not well-known outside Denmark but its a global leader in intimate healthcare with products patients rely on daily and often stay with for decades creating an incredibly durable customer base. I just updated my full Coloplast analysis you can read it here:"
X Link 2025-11-30T16:23Z 4886 followers, 10.2K engagements

"Bank of America raises its price target on $NVO to XXX DKK from XXX DKK while keeping a neutral rating according to a note from BofA Securities. #StocksToWatch #Invest"
X Link 2025-12-01T09:35Z 4880 followers, 3838 engagements

"$NVO s and Lundbecks owner funds have invested in a new Danish pharma company called QuantumCell. Founded in June 2025 in Copenhagen it focuses on the research development and commercialisation of medicines. Other investors include life-science venture funds Sofinnova Forbion and First Spark. To my knowledge its therapeutic focus has not been publicly disclosed. #Stocks #Investing"
X Link 2025-12-02T21:28Z 4881 followers, 1946 engagements

"Why $NVO is paying up to $2.1B for Zaltenibart a Phase X drug not a full company. Zaltenibart blocks MASP-3 helping calm an overactive immune pathway that can damage red blood cells and kidneys. In early trials for PNH a rare disease where the immune system destroys red blood cells the drug improved hemoglobin and reduced signs of cell damage. Novo gets full global rights; Omeros keeps its small-molecule MASP-3 program and some older antibody rights. Complement diseases are rare but very high-value with current treatments often costing $500k per patient per year. Zaltenibart might also be"
X Link 2025-12-03T08:51Z 4881 followers, 2712 engagements

"Denmark is examining whether $NVO could be held liable for compensation claims linked to serious Wegovy-related vision injuries but legal experts say Novo will likely avoid paying. A health law scholar notes the company can argue these are development injuries meaning side effects that couldnt have been known when the drug was approved. Whether Novo first became aware of a possible link is key. Two Danish studies in late 2024 suggested a connection and severe vision loss was added as a side effect this October. Novo still maintains there is no proven causal link. The state rarely seeks"
X Link 2025-12-04T08:09Z 4881 followers, 1904 engagements

"#Denmark just raised its 2025 growth outlook to XXX% among the fastest in Europe driven largely by the pharma sector even as $NVO faces layoffs slower growth and rising GLP-1 competition. Meanwhile the Danish #StockMarket has been one of the weakest in 2025 leaving several high-quality companies including Novo trading at their lowest valuations in years. A strong economy but equity prices that dont reflect it"
X Link 2025-12-05T08:34Z 4886 followers, 2246 engagements

"I recently wrote about Healthifys partnership with $NVO in India but the companys ambitions are much bigger. Healthify plans to become the leading global patient-support provider for all GLP-1 drugmakers. After signing its first deal with Novo Nordisk India its now seeking partnerships with other pharma companies as the weight-loss market booms. Healthify already serves 45M users and its GLP-1 program is its fastest-growing offering expected to make up over a third of paid subscriptions next year. Link to article: #stocks #Investing"
X Link 2025-12-06T14:22Z 4880 followers, 1672 engagements

"$AHT.L reports earnings Tuesday and its a much more interesting business than most people realise. Its one of the largest equipment rental companies in North America and the U.K. (Sunbelt Rentals) and its real edge is scale: dense branch networks clustered locations in major cities faster delivery higher availability and the ability to serve everyone from small contractors to national builders. Read my full analysis here: #StocksToWatch #investingtips"
X Link 2025-12-08T05:45Z 4880 followers, XXX engagements

"$GMAB delivered a strong overall impression with its new Epkinly (epcoritamab) data over the weekend says Jyske Bank analyst Henrik Hallengreen Laustsen. Multiple studies were presented at ASH a Phase X in second-line follicular lymphoma plus Phase 1b/2 and Phase X studies in first-line FL and DLBCL. Henrik Hallengreen Laustsen says the results look solid showing Genmab has a good product that holds up well against competitors across treatment lines. Genmab shares rose XXX% to 2050 DKK on Monday helped by what Henrik Hallengreen Laustsen calls a strong overall impression and continued"
X Link 2025-12-08T12:37Z 4880 followers, 1071 engagements

"$MOMO reports earnings on Wednesday. Often called the Chinese Tinder the stock is still trading below book value. Full analysis here: #StocksToWatch #invest"
X Link 2025-12-08T20:33Z 4878 followers, XXX engagements

"Samantha McLemore from Patient Capital Management increased her position in $RPRX once again last quarter. #WarrenBuffett once owned the stock but exited quickly. Royalty Pharma still flies under the radar despite its unique royalty-based model that offers exposure to pharma with lower risk. #StocksToWatch #investing"
X Link 2025-10-30T15:16Z 4889 followers, 1149 engagements

"Novo Holdings the controlling shareholder of $NVO is selling its entire XXX% stake in medical device maker Convatec. It plans to sell about XXX million shares worth roughly XXX million pounds based on Mondays closing price. The shares will be sold quickly to institutional investors and the final price will be set shortly. #StocksToWatch #investing"
X Link 2025-11-17T21:35Z 4890 followers, 2541 engagements

"The Danish C25 index closed up XXX% on Monday. Top X performers: GN Store Nord: +2.9% Maersk B: +2.6% Maersk A: +2.3% Royal Unibrew: +2.1% Coloplast: +1.5% Bottom 5: Zealand Pharma: -XXX% Ambu: -XXX% NKT: -XXX% $NVO: -XXX% Rockwool: -XXX% #Stocks #Investing"
X Link 2025-12-01T16:27Z 4891 followers, 1131 engagements

"$UNFI reports earnings on Tuesday. United Natural Foods is one of the largest food distributors in North America connecting thousands of producers with retailers ranging from small local stores to major players like Whole Foods. Its scale national network and focus on natural & sustainable foods make it an important company in the grocery supply chain. Full analysis: #Stocks #Investing"
X Link 2025-12-01T20:33Z 4889 followers, 1006 engagements

"Morgan Stanley cuts its price target on $NVO to DKK XXX (from 280) and reiterates its Underweight rating. #StocksToWatch"
X Link 2025-12-03T09:29Z 4890 followers, 1356 engagements

"Akero Therapeutics shareholders have approved the companys sale to $NVO. The deal is worth up to $5.2B: shareholders will get $XX per share in cash plus a possible extra $X per share if Akeros drug efruxifermin is approved by 2031. U.S. regulators have already cleared the antitrust waiting period and the companies expect the merger to close around year-end once remaining approvals are completed. #StockslnFocus #Investing"
X Link 2025-12-03T17:27Z 4893 followers, 2570 engagements

"@FIREDUpWealth Not considering valuation $TDG $IDXX and $MSFT. Considering valuation it would be $NVO $POOL and $AMS.MC"
X Link 2025-12-03T20:07Z 4889 followers, 1873 engagements

"Mike Doutsdar just held his first Open Mike town hall with $NVO colleagues worldwide. No surprise that a key theme was putting the patient at the center something hes emphasized in every interview I have heard. Its the core of Novos heritage and he says it will continue to drive innovation and growth for years to come. #StocksToWatch #Investing"
X Link 2025-12-06T08:42Z 4893 followers, 2552 engagements

"$JPM says one of Denmarks C25 stocks could nearly double in the coming months: $ZEAL. The bank lowered its price target slightly from 1050 DKK to 1000 DKK but that still implies XX% upside from Mondays opening price of XXX DKK and JPMorgan keeps an Overweight rating. Zealand Pharma which is developing multiple obesity and metabolic drugs now has one of the most bullish analyst outlooks in the sector: Highest PT: 1120 DKK (KBC Securities) Next: 1050 DKK (Jefferies) JPMorgans 1000 DKK is the third-highest among XX analysts Average PT: XXX DKK (+45% upside) Ratings: XX Buy X Hold X Sell The"
X Link 2025-12-08T11:15Z 4890 followers, 1026 engagements

"The $NVO Haemophilia & Haemoglobinopathies Foundation (NNHF) has expanded its mission. Since 2005 it has supported haemophilia care in low- and middle-income countries and will now also include sickle cell disease and thalassaemia conditions affecting over 10M people worldwide. NNHF will continue its partnership-based model focusing on local programmes education advocacy and long-term sustainable care. Link to announcement: #stocks #Investing"
X Link 2025-12-08T19:28Z 4893 followers, 2273 engagements

"I just updated my full analysis of $TDG and its the longest deep dive I have ever written. Around XX% of TDGs sales come from components it uniquely designs and owns and roughly 7580% of revenue comes from parts where TransDigm is the only approved supplier. These are mission-critical products with long lifecycles and strong pricing power. Its a company I would love to add to the portfolio one day. Read the full analysis here: #Stocks #Invest"
X Link 2025-11-28T20:34Z 4893 followers, 1802 engagements

"Investor Lau Svenssen says $NVO is one of three stocks he plans to bet on next year despite a tough 2025 for shareholders. He expects the stock to climb to 450500 DKK by end-2026 a 4258% gain from current levels. Lau Svenssen believes Novo is getting control of copycat pressure and sees upside from the upcoming obesity pill and progress on CagriSema. Risks remain but he thinks Novo has found the bottom and is ready to rebound. Link to article (in Danish): #StocksToWatch #Investing"
X Link 2025-12-01T08:39Z 4893 followers, 9607 engagements

"@joecarlsonshow Prosus $NVO and $BABA"
X Link 2025-12-03T16:06Z 4893 followers, 6337 engagements

"Another reason Denmarks #StockMarke has lagged almost every major market this year: foreign investors have been net sellers of key Danish names. Foreigners sold DKK 36bn of $NVO B-shares in the first XX months of 2025 (though they still own 77%). Meanwhile they bought DKK 38bn of rsted mostly tied to the capital raise. Denmarks central bank reports that Danish investors poured DKK 131bn into foreign equities while foreigners bought only DKK 6bn in Danish stocks. It means that several high-quality Danish companies are trading at their lowest valuations in years. #StocksToWatch #Investing"
X Link 2025-12-05T09:44Z 4893 followers, 2062 engagements

"This may explain why $NVO is up and $HIMS is down today. Two U.S. lawmakers have introduced the SAFE Drugs Act of 2025 a bill targeting unsafe unapproved mass-compounded drugs including compounded GLP-1s. It would tighten FDA oversight increase inspections and strengthen reporting requirements. Link: #StocksInFocus #Investing"
X Link 2025-12-10T20:37Z 4893 followers, 5208 engagements

"Reuters reports that FDA leadership has pushed to shorten the initial review of $LLY s new weight-loss pill from XX days to as little as one week at the companys request. After internal criticism regulators are now considering a XX week review window depending on complexity. If approved a decision could come as early as March XX versus the original May XX deadline. Competitor $NVO is expected to launch its own obesity pill in December or January. Both companies dominate the obesity market which analysts estimate could reach $150B annually in the early 2030s. Link to article: #StocksToWatch"
X Link 2025-12-12T12:53Z 4893 followers, 2676 engagements

"Jumbo Interactive ( $JIN ) jumps +8% after announcing its entry into the UK prize draw market with the acquisition of Dream Car Giveaways a leading B2C platform offering car cash and lifestyle prizes. The deal worth A$109.9M marks Jumbos biggest step yet in expanding internationally. DCG generated A$118M in TTV and A$17.9M in revenue over the past year and the acquisition is expected to be EPS accretive within XX months. With a 6.5x EBITDA multiple and 2025% EBITDA growth expected the deal looks like a strong strategic move and despite todays jump the shares still look cheap. Read my full"
X Link 2025-10-15T07:40Z 4893 followers, XXX engagements

"$NVO has now completed its acquisition of Akero Therapeutics. Novo Nordisk paid $54/share in cash (about $4.7B) and will pay another $6/share if Akeros MASH drug EFX gets U.S. approval bringing the total deal to about $5.2B. Akero is now fully owned by Novo and will be delisted from Nasdaq. The deal gives Novo a strong late-stage MASH candidate as part of its expanding pipeline. Link to announcement: #stocks #Investing"
X Link 2025-12-09T14:21Z 4893 followers, 4242 engagements

"$COST reports earnings tonight. The late Charlie Munger once said: I love everything about #costco . Im a complete addict and I will never sell a share. But is now the right time to buy Read my full analysis here: #Stocks #Invest"
X Link 2025-12-11T20:16Z 4893 followers, XXX engagements

"Analysts now expect $NVO to shrink in 2026. After a XX% share price drop over the past XX months consensus estimates (Bloomberg) point to declining growth next year pressured by competition copycats and lower obesity drug prices. 2025 revenue est.: DKK 308bn 2026 revenue est.: DKK 304.7bn (-1%) 2026 EPS seen at DKK XXXX vs XXXX in 2025 (-4%) Some banks are more cautious: Morgan Stanley expects 2026 revenue growth of -X% to +3% That implies revenue could fall to DKK 292bn Link to article (in Danish): #StocksToWatch #Investing"
X Link 2025-12-12T08:07Z 4893 followers, 7721 engagements

"Nykredit cuts its price target on $NVO to DKK XXX from DKK XXX but reiterates its Buy rating on the stock. #StocksToWatch #Investing"
X Link 2025-12-12T14:06Z 4893 followers, XXX engagements

"Everyone is focused on $NVO and $LLY but Zealand Pharma shouldnt be forgotten. Roche has ambitions to become a top-3 obesity player and its major partnership with Zealand puts the Danish biotech right in the spotlight. Zealands stock is rising for the third straight day reminding investors how quickly the obesity-drug narrative can shift. What the momentum shows: The weight-loss market is highly volatile Its not just Novo & Lilly Roche/Zealand are serious contenders Investors are recognizing Zealands pipeline strength With major data coming from Survodutide and Petrilintide in the next"
X Link 2025-11-13T14:32Z 4893 followers, 1020 engagements

"The Danish C25 index closed down X% on Thursday. $NVO ended the day down XXX% while Zealand Pharma was the days winner after investors reacted positively to fresh updates in its Q3 report. At the other end of the index momentum faded for Vestas as the stock fell XXX% today #stocks #investing #Denmark"
X Link 2025-11-13T17:58Z 4893 followers, XXX engagements

"The Danish C25 ended Thursday up 0.4%. $NVO rose XXX% while Zealand Pharma jumped 6.8%. rsted (+3.5%) and Vestas (+2.3%) were also among the winners as Denmark opened tenders for three new offshore wind parks with a combined capacity of at least XXX GW. #Stocks #investing"
X Link 2025-11-20T19:20Z 4893 followers, 1109 engagements

"Omeros and $NVO have officially closed their deal for zaltenibart (OMS906) a Phase X MASP-3targeting antibody for rare blood & kidney disorders a transaction worth up to $2.1B. Omeros receives: $240M upfront (paid at closing) Up to $340M in upfront + near-term milestones Up to $2.1B total milestones Tiered royalties on future sales Novo Nordisk plans to develop zaltenibart as a potentially best-in-class treatment across multiple complement-driven diseases strengthening its rare-disease pipeline. Link to announcement: #stocks #Investing"
X Link 2025-12-01T14:30Z 4894 followers, 3046 engagements

"Interesting prescription news for $NVO"
X Link 2025-12-01T19:47Z 4894 followers, 7937 engagements

"Canaccord Genuitys Quest unit part of one of Canadas largest independent investment banks just added $NVO to its list of preferred stocks saying the market is pricing almost none of Novos future growth. After an 18-month free fall they call it a very cheap value creator. #Stocks #Investing"
X Link 2025-12-02T09:29Z 4894 followers, 2778 engagements

"Some good news for $NVO in India"
X Link 2025-12-02T17:25Z 4894 followers, 8962 engagements

"$NVO and the banks helped lift the Danish market on Friday with the C25 index up 0.3%. Coloplast finished XXX% lower but the drop reflected the stock going ex-dividend with a payout of DKK XX per share. The dividend will be paid out on Tuesday. #Stocks #Investing"
X Link 2025-12-05T22:58Z 4894 followers, 1896 engagements

"J.P. Morgan cuts its price target on $NVO to XXX DKK (from 500) but reiterates its Overweight rating. #stocks #Investing"
X Link 2025-12-08T10:33Z 4894 followers, 7353 engagements

"Argus Research has downgraded $NVO's ADR to Hold from Buy. #stocks #investment"
X Link 2025-12-08T14:07Z 4894 followers, 3208 engagements

"A busy morning in biotech is putting pressure on $NVO and $LLY. Structure Therapeutics reported strong Phase X results for its oral weight-loss pill (up to XXXX% loss in XX weeks) while WAVE Life Sciences shared early data showing a XXX% fat reduction from a single dose. Both programs are still early but they highlight the growing pipeline of challengers aiming at the obesity market dominated by Novo and Lilly. Link to article: #stocks #Investing"
X Link 2025-12-08T21:28Z 4894 followers, 2694 engagements

"$OXM reports earnings tonight. Oxford Industries is a major player in premium lifestyle apparel think Tommy Bahama Lilly Pulitzer and Johnny Was. With strong DTC execution pricing power loyal customers and an attractive valuation is it time to buy Full analysis here: #StocksToWatch #Investing"
X Link 2025-12-10T10:11Z 4893 followers, XXX engagements

"$NVO isnt the only Danish company focused on obesity. Zealand Pharma just unveiled its Metabolic Frontier 2030 strategy ahead of its Capital Markets Day in London aiming to become a clear leader in obesity & metabolic health. The goals by 2030: X product launches 10+ clinical programs in the pipeline Major readouts coming in 2026 (Petrelintide Phase X Survodutide Phase 3) CEO Adam Steensberg calls it a pivotal day as $ZEAL sets out to build a biotech company that can fundamentally change how obesity and metabolic diseases are treated. I own a small position in Zealand Pharma #Stocks #Investing"
X Link 2025-12-11T08:33Z 4894 followers, 1562 engagements

"$RMD reports earnings Thursday. ResMed is a global leader in sleep and respiratory care best known for its devices that treat sleep apnea. It also earns steady recurring revenue from masks and accessories that patients regularly replace a key driver of profits and cash flow. Full analysis: #StocksToWatch #investing"
X Link 2025-10-30T08:40Z 4894 followers, XXX engagements

"$TDG reports earnings Thursday. TransDigm is a leader in aerospace supplying proprietary and mission-critical components found in nearly every commercial and military aircraft. With about XX% of revenue coming from proprietary parts and XX% from sole-sourced components its pricing power is exceptional. Full analysis: #StocksToWatch #investing"
X Link 2025-11-05T14:06Z 4894 followers, 1208 engagements

"Per Hansen from Nordnet highlights that while everyone is focused on $NVO $LLY and $PFE after the Metsera bidding war investors may be overlooking Zealand Pharma: Roche aims to become a top-3 player in obesity and has partnered with Zealand in a $5.3B deal around Petrinlintide Zealand received $1.4B upfront yearly payments and 50/50 profit sharing in the US/EU Key data coming soon: Zupreme X (Q4 2025) and Zupreme X (1H 2026) Zealand also co-owns CT-388 which showed XX% average weight loss after XX weeks Other assets include Survodutide (with Boehringer Ingelheim Phase 3) and Dapiglutide"
X Link 2025-11-10T18:20Z 4894 followers, 2401 engagements

"The Danish C25 index fell XXX% on Monday. rsted led the gains with a rise of XXX% followed by Bavarian Nordic at XXX% and Zealand Pharma at 2.1%. $NVO was up XXX percent after announcing lower U.S. pricing for Ozempic and Wegovy. #stocks #investing #Denmark"
X Link 2025-11-17T17:30Z 4894 followers, 1206 engagements

"Zealand Pharma CEO Adam Steensberg just made some bold comments about the companys potential obesity drug petrelentide. Speaking at a health conference in London he said petrelentide could be developed into a monthly product and may match or even exceed treatments from $NVO and $LLY. Were likely 510x more potent with similar tolerability Adam Steensberg said comparing it to Lillys elorantide. #StocksToWatch #investing"
X Link 2025-11-20T18:02Z 4894 followers, 1464 engagements

"$CPRT reports earnings tonight. Copart runs one of the worlds largest online vehicle auction platforms connecting insurance companies dealers rental fleets and buyers across the globe. When a car is damaged or totaled it often ends up being sold through Copart. Its a business I would love to own. Full analysis here: #StocksToWatch #investing"
X Link 2025-11-20T20:44Z 4894 followers, 1428 engagements

"Evotec and $NVO just launched LAB eN a new drug-discovery accelerator turning academic research into real therapeutics. Why it matters: This could reshape how early drug ideas move into development. Key points: LAB eN will focus on cardiometabolic + rare endocrine/blood diseases Creates a pipeline of early-stage projects that will eventually need manufacturing partners CDMOs (contract manufacturers) may need more flexible contracts modular capacity faster scale-up and better regulatory alignment Expect growing demand for small-batch GMP work single-use bioprocessing advanced analytics and"
X Link 2025-11-22T11:24Z 4894 followers, 2564 engagements

"The Danish C25 index closed up XXX% on Thursday its third straight day in the green. $NVO finished XXXX% lower after Handelsbanken downgraded the stock arguing market expectations are too high. At the top of the index was GN Store Nord jumping 5.9%. #StockMarket #Denmark"
X Link 2025-11-27T17:28Z 4894 followers, 1572 engagements

"A few more words on why Bank of America raised its price target on $NVO: BofA sees several positives ahead including the upcoming launch of oral semaglutide and the FDA filing for a higher XXX mg Wegovy dose which they say could help close the competitive gap with Lillys Zepbound. These offset concerns about slowing growth 2026 sales expectations and CagriSema risks leading BofA to lift its target despite keeping a neutral rating. #Stocks #Investing"
X Link 2025-12-01T10:16Z 4894 followers, 6024 engagements

"The U.S. and U.K. just struck a major drug-pricing deal one that could benefit all global pharma players including $NVO and $LLY. Britain will raise the net price it pays for new patented medicines by XX% and overhaul its tax system to ease the burden on drugmakers in exchange for zero U.S. tariffs on U.K. pharmaceutical exports for at least three years. The deal marks a key win for Trumps push to get other countries to pay more for medicines instead of relying on U.S. patients to subsidize global prices. Link to article: #Stocks #Investing"
X Link 2025-12-02T05:03Z 4894 followers, 3125 engagements

"$NVO is planning a global pediatric trial of CagriSema for obesity per Bloomberg. The study will enroll XXX children aged 8+ with XX weeks of treatment. Top-line results arent expected until around 2030. Participants will be assigned to one of four arms: CagriSema Wegovy cagrilintide or placebo. #Stocks #Investing"
X Link 2025-12-02T15:05Z 4894 followers, 4111 engagements

"$NVO sentiment is weak but the company is quietly strengthening its future position. Its expanding its semaglutide portfolio (incl. a higher XXX mg Wegovy dose with XX% weight loss) advancing follow-ups like Amycretin and preparing an oral Wegovy that could unlock the mass market. Novo is also leaning into pricing + access reforms in the US. Lower margins short term but far broader coverage long term. With innovation easier delivery forms and expanded access Novo aims to accelerate growth over the next decade even as competition from Lilly intensifies. Link to article: #Stocks #Investing"
X Link 2025-12-02T18:35Z 4894 followers, 3527 engagements

"Prosus repurchased another 1810829 shares at an average price of XXXXX last week. Since June XX 2022 it has bought back XX% of its shares outstanding (through Sept XX 2025). It remains my largest position ahead of $NVO. #Stocks #Investing"
X Link 2025-12-02T19:29Z 4894 followers, 2812 engagements

"Johannes Mller from MW Compounders highlights three stocks he believes can create strong returns in 2026 and one of them is $NVO. After being heavily sold off since summer 2024 he thinks sentiment will improve next year. Novos cost cuts of 9000 jobs are expected to show up in 2026 numbers and a comeback could strengthen if it regains share from Eli Lilly slows copycat competition and delivers positive pipeline news. He points to CagriSema and especially Amycretin as potential bright spots. Link to article: #StocksToWatch"
X Link 2025-12-03T07:00Z 4894 followers, 3272 engagements

"$NVO has filed a third application for state reimbursement of its weight-loss drug Wegovy in Denmark after being rejected twice. The move comes shortly after the WHO issued its first guidelines recommending broader access to obesity treatments which Novo hopes will support its case. About 900000 Danes are classified as obese and full reimbursement could cost the state billions. #Stocks #investment"
X Link 2025-12-03T14:52Z 4894 followers, 3179 engagements

"$NVO is preparing to launch Ozempic in India this month per Reuters. With India home to the worlds second-largest type X diabetes population and fast-rising obesity rates the country is a major battleground for GLP-1 drugs. Novo wants Ozempic on the market before cheaper generics arrive in 2026. Wegovy faces tough competition from Eli Lillys Mounjaro which is already Indias top-selling drug by value. Ozempics launch would strengthen Novos position in India where it already has a strong diabetes franchise with Rybelsus. Link to article: #Stocks"
X Link 2025-12-03T21:46Z 4894 followers, 4943 engagements

"$NVO says it may keep exploring its oral Ozempic pill for Alzheimers even after two failed trials. At the CTAD conference the company shared new data showing small (10% or less) reductions in several biological markers tied to Alzheimers including inflammation neurodegeneration and tau based on spinal fluid tests. The drug didnt improve cognition but Novo says these biological signals suggest there may still be something worth investigating. #StocksToWatch #Investing"
X Link 2025-12-04T09:03Z 4894 followers, 6924 engagements

"Swedbank says $NVO is set to maintain its position as the global leader in diabetes and obesity driven by GLP-1 drugs like Ozempic and Wegovy. The expected launches of oral semaglutide and CagriSema are highlighted as key growth drivers and the new U.S. pricing agreement is seen as a positive from 2027. #Stocks #Investing"
X Link 2025-12-04T13:25Z 4894 followers, 4899 engagements

"For the second time in a month Zacks has cut its price target on $NVO s U.S.-listed shares now down to $XX from $XX after a cut from $XX in November. The rating is also lowered to Underperform from Neutral. #StocksInFocus #Investing"
X Link 2025-12-05T06:35Z 4894 followers, 2544 engagements

"$NVO is warning U.S. consumers about counterfeit Ozempic X mg pens after the FDA seized fake units sold outside the authorized supply chain. The contents are still unknown and may pose safety risks. Counterfeits remain a major issue for both Novo Nordisk and $LLY hopefully well see tougher penalties for those distributing them. Link to announcement: #stocks #Investing"
X Link 2025-12-06T11:19Z 4894 followers, 4098 engagements

"The Week of $NVO: India Launch Analyst Cuts Rare-Disease Expansion Reimbursement Fight & Global Partnerships New partnerships & global expansion Novo signed a new MoU with Egypts Healthcare Authority to strengthen care for hemophilia and blood disorders through training earlier diagnosis updated protocols and expanded access. Novo will launch Ozempic in India this month aiming to establish market presence before generics arrive in 2026. India has the worlds #2 diabetes population and fast-rising obesity. Novo also partnered with Healthify in India on an AI-enabled obesity support program with"
X Link 2025-12-07T17:14Z 4894 followers, 2688 engagements

"$GMAB just reported strong Phase X results for Epkinly in combination with Rituximab + Lenalidomide in follicular lymphoma. At the ASH meeting Genmab said the combo reduced the risk of disease progression or death by XX% vs Rituximab + Lenalidomide alone. In November the FDA approved this combination as a second-line treatment for relapsed or refractory follicular lymphoma. #StocksToWatch #Investing"
X Link 2025-12-08T09:22Z 4894 followers, 1007 engagements

"Structure Therapeutics just reported positive Phase X results for its once-daily oral weight-loss pill Aleniglipron which may explain the drop in $NVO today. After XX weeks: XXX mg dose: XXXX% placebo-adjusted weight loss XXX mg dose: up to XXXX% placebo-adjusted weight loss Discontinuation due to side effects: XXXX% The company says the higher-dose results may be the best in class so far for oral small-molecule GLP-1s and provides strong justification to move into Phase X. Structure Therapeutics plans to start Phase X trials in mid-2026. #StocksToWatch #InvestingTips"
X Link 2025-12-08T15:04Z 4894 followers, 4117 engagements

"$NVO is preparing a global trial of its next-generation obesity drugs (including CagriSema) in children as young as X a move experts say raises ethical dilemmas. The study will run in XX countries including Denmark. Specialists note that severe childhood obesity is real and sometimes requires treatment but long-term GLP-1 safety in kids remains uncertain. A key detail: EU and U.S. regulators reward companies for pediatric trials by extending patent protection roughly six months giving drugmakers a longer period of market exclusivity. That incentive combined with rising medical need explains"
X Link 2025-12-08T16:10Z 4894 followers, 3119 engagements

"The Danish C25 index slipped XXX% on Monday. Zealand Pharma led the index rising XXX% while $NVO fell XXX% on the day. #stocks #Investing"
X Link 2025-12-08T18:18Z 4894 followers, 1096 engagements

"Kepler Cheuvreux says the market may be seriously undervaluing $NVO especially if oral semaglutide takes a larger share of the U.S. obesity market than expected and if CagriSema outperforms Lillys Zepbound in upcoming data. Kepler keeps its Buy rating and XXX DKK target (vs. XXX DKK close) implying 50%+ upside. They argue: Novos struggles vs. Zepbound are already fully priced in What isnt priced in: the first/leading oral obesity drug + a more competitive next-gen injectable (CagriSema) Consensus expects just XXX% U.S. market share for the pill in 2026 which Kepler calls a major underestimate"
X Link 2025-12-09T07:38Z 4893 followers, 9435 engagements

"$NVO has moved the Delhi High Court to stop Sun Pharma from launching a generic version of semaglutide as the drugs Indian patent expiry (March 2026) approaches. The case has been transferred to the same bench handling Novos ongoing litigation against Dr. Reddys and Natco. Last week the court allowed Dr. Reddys to manufacture and export semaglutide to non-patent countries until 2026 but barred domestic sales. With multiple Indian pharma companies preparing for generics the battle for the countrys fast-growing GLP-1 market is clearly heating up. Link to article: #StocksToWatch #Investing"
X Link 2025-12-09T12:52Z 4894 followers, 3122 engagements

"The Danish C25 index slipped XXX% on Tuesday. Biotech names weighed on the index with Zealand Pharma the biggest decliner of the day. Genmab also fell 2.2%. $NVO finished the session almost flat up 0.07%. #StockMarket #Invest"
X Link 2025-12-09T17:22Z 4894 followers, XXX engagements

"The Danish C25 index closed up XXX% today Top X in the C25: Vestas +4.2% Maersk B +3.4% $NVO +3.3% GN Store Nord +3.2% Maersk A +2.7% Bottom 5: Pandora XXX% ISS XXX% Novonesis XXX% rsted XXX% Genmab XXX% #stocks #Investing"
X Link 2025-12-10T16:34Z 4894 followers, 1113 engagements

"Semaglutide the active ingredient in $NVO s Ozempic & Wegovy will lose patent protection in major markets like India China & Brazil in 2026. Generic makers are gearing up fast analysts say prices could fall up to XX% as Indian & Chinese firms launch copycats. These markets account for XX% of the worlds adults living with obesity. Demand for GLP-1s is so massive that dozens of companies are already preparing Phase X trials manufacturing capacity and bulk peptide supply. A huge shift is coming to global obesity treatment and the competitive landscape for Novo Nordisk. Link to article:"
X Link 2025-12-10T18:46Z 4893 followers, 3414 engagements

"$ZEAL announced a new strategic partnership with OTR Therapeutics to develop next-generation treatments for metabolic diseases. OTR will receive a $20M upfront payment and up to $2.5B in milestones and differentiated royalties. The collaboration combines Zealand Pharmas expertise in obesity & metabolic health with OTRs R&D platform. OTR will lead preclinical development while Zealand will take programs through clinical stages regulatory filings and global commercialization. (Zealand Pharma is holding a Capital Markets Day in London today.) #Stocks #Investing"
X Link 2025-12-11T08:03Z 4894 followers, XXX engagements

"$LULU reports earnings tonight. 2025 has been rough the stock is down XX% and now trades at what looks like an attractive valuation. But is it time to buy Full analysis here: #Stocks #Investing"
X Link 2025-12-11T10:11Z 4894 followers, XXX engagements

"The Danish C25 index closed up XXX% on Thursday helped by $NVO which gained 3.4%. But Novo wasnt the top performer today: GN Store Nord and A.P. Mller-Mrsk both finished even stronger. #StocksToWatch #Invest #Denmark"
X Link 2025-12-11T16:42Z 4894 followers, XXX engagements

"Im XX% in cash right now. Besides $NVO what #stocks look interesting at current valuations It doesnt matter which market. Drop some tickers for me to research"
X Link 2025-10-26T18:27Z 4894 followers, 14.7K engagements

"$NVO reported top-line results from the evoke/evoke+ Alzheimers trials: oral semaglutide was safe but didnt slow disease progression vs placebo despite biomarker improvements. The extension phase will be discontinued. Link to announcement: #StocksToWatch #investing"
X Link 2025-11-24T11:30Z 4894 followers, 16.7K engagements

"$NVO says it launched its 2020 Alzheimers trials for semaglutide based on human animal and real-world data suggesting GLP-1 activity in the brain. The studies ultimately failed but Novos Peter Johannsen says it was a scientific question that needed an answer. He noted Alzheimers remains highly complex with many unknowns beyond amyloid. Novo will present initial data from its two 2-year Rybelsus Alzheimers trials this week with full results due in March. Real-world analyses have hinted at cognitive benefits for diabetes patients on GLP-1s but Peter Johannsen cautioned that these studies"
X Link 2025-12-03T10:11Z 4894 followers, 5224 engagements

"A bullish thesis on $NVO is making the rounds on the Value Investing subreddit. The argument: despite sentiment weakness and a XX% drop since spring fundamentals remain strong. Revenue has doubled in five years on GLP-1 demand margins have expanded cash flow is robust and investments in capacity are reshaping the balance sheet. A conservative DCF suggests fair value around $XXXXX per share with meaningful upside if GLP-1 momentum continues. Risks remain (competition regulation scaling) but the long-term financial story is still compelling. Link to article: #Stocks #Investing"
X Link 2025-12-04T18:34Z 4894 followers, 4690 engagements

"After meeting with $NVO s CFO Berenberg says the focus is on next years launch of the Wegovy pill but they still expect major headwinds in 2026. The bank forecasts X% revenue and X% EPS growth citing semaglutide patent expiries outside the US U.S. price cuts rebate changes and inventory reductions. Novo expects U.S. approval of the obesity pill by year-end. Despite the challenges Berenberg reiterates Buy with a DKK XXX target pointing to strong 2026 catalysts. #StocksToWatch #Investing"
X Link 2025-12-05T10:38Z 4894 followers, 6117 engagements

"Mill Chart just updated its analysis of $NVO and it screens as a textbook quality-investing company. Novo posts an extraordinary XX% ROIC strong margin expansion a 5-year EBIT CAGR of XXXX% and a Debt/FCF ratio of just XXXX. It also scores highly on profitability and long-term durability supported by global leadership in diabetes and obesity care. A deeper look at the numbers and the business makes a strong case for NVO as a long-term compounder. Link to analysis: #Stocks #Investing"
X Link 2025-12-06T16:41Z 4894 followers, 4069 engagements

"I haven't seen this mentioned before a new study suggests obesity may accelerate the development of Alzheimers an area of interest for companies like $NVO given the link between obesity and long-term brain health. Researchers tracked XXX people for X years and found Alzheimers biomarkers rose much faster in those with obesity with blood tests detecting changes earlier than PET scans. Link to article: #StocksToWatch #investingtips"
X Link 2025-12-07T09:58Z 4894 followers, 3135 engagements

"An analysis by Fifty Or Nothing breaks down what revenues $LLY and $NVO would need to justify their current market caps. To justify $948B Eli Lilly would need revenue to grow from $59B to $168B in X years (23% CAGR). For Novo Nordisk today's valuation implies a -XXX% annual revenue decline over X years even though the company guides for X% growth. Link to analysis: #StocksToWatch #Investing"
X Link 2025-12-07T13:25Z 4893 followers, 14K engagements

"China has added $LLY Mounjaro to its national health insurance list starting Jan X for type X diabetes. The drug is also approved in China for obesity and sleep apnea. $NVO Ozempic has been on Chinas reimbursement list since 2022 so this brings Mounjaro in line with its main competitor in the market. #StocksToWatch #Investing"
X Link 2025-12-08T07:12Z 4893 followers, 4153 engagements

"Commentary from Per Hansen Investment Economist at Nordnet: Most expect FDA approval of $NVO 's Wegovy pill within the coming weeks. Approval could help stabilize sentiment but Per Hansen argues that investors are really waiting for a cocktail of positive signals before believing in a true long-term turnaround. Key points: FDA approval of the Wegovy tablet is widely expected anything less than a clean approval would be a major shock and likely push the stock lower. A big rally on approval alone is unlikely; markets want confirmation not just expectation. What comes next Investors will look"
X Link 2025-12-08T08:18Z 4893 followers, 5188 engagements

"HSBC just raised its price target on $NVO by XXXX% from XXX DKK to XXX DKK implying about XX% upside from current levels. The bank keeps its Hold rating but says Novo Nordisks shares may have more room to run. #StocksToWatch #Investing"
X Link 2025-12-10T06:23Z 4894 followers, 3851 engagements

"Lars Hytting (ArthaScope) has picked three stocks he believes can beat the market in 2026 and one of them is $NVO. After a tough year with the stock down XX% he expects Novo Nordisk to rebound seeing potential for a 1015% gain next year. He says the worst is priced in: Were at a point where no news is good news. Key catalysts hes watching: the Wegovy pill launch and upcoming obesity-drug data both of which he expects to deliver. Link to article (in Danish): #StocksToWatch #Investing"
X Link 2025-12-10T07:27Z 4893 followers, 6650 engagements

"New data from Denmarks Patient Compensation Association shows a rising number of patients seeking compensation for NAION a rare eye condition allegedly linked to $NVO s Wegovy and Ozempic. So far XX claims have been filed and X cases decided with X patients granted compensation. NAION affects the optic nerve and can cause vision loss but remains very rare: fewer than X in 10000 users of Wegovy Ozempic or Rybelsus. #StocksToWatch #Invest"
X Link 2025-12-10T14:15Z 4893 followers, 2714 engagements

"SEB cut its price target on $NVO today by XX% from XXX DKK to XXX DKK citing expectations of a significant Wegovy price drop in the U.S. in 2026. SEB now models: X% organic growth globally in 2026 XX% in the U.S. due to price pressure on both Wegovy and Ozempic Despite this analyst Martin Parkhi keeps a Buy rating. The new target still implies 40%+ upside from Wednesdays close . SEB expects growth to return in 2027 driven by new products and improved access. #Stocks #Investing"
X Link 2025-12-11T07:19Z 4893 followers, 2622 engagements

"landsbanken says the proposed U.S. SAFE Drugs Act is a step in the right direction tightening rules on compounded GLP-1 products that have been pressuring $NVO s sales. If the bill becomes law the bank expects it could positively impact Novos U.S. weight-loss drug sales. #Stocks #Investing"
X Link 2025-12-11T09:01Z 4893 followers, 1525 engagements

"Yesterday $NVO rose and $HIMS dropped as two U.S. lawmakers introduced the SAFE Drugs Act of 2025 a bill targeting unsafe unapproved mass-compounded drugs including compounded GLP-1s. The act would tighten the rules so pharmacies cant mass-produce copycat versions of FDA-approved drugs and it would require any pharmacy shipping more than XX prescriptions across state lines to report it to the FDA. The bill has support from groups like the American Diabetes Association which warns that compounded GLP-1s come with uncertainty about their content safety quality and effectiveness. The FDA has"
X Link 2025-12-11T11:19Z 4893 followers, 4396 engagements

"A Danish portfolio manager sees strong upside in the Danish market and picks $NVO as one of his top stocks for 2026. Johnny Madsen CIO at Formue & Investeringspleje says sentiment around Novo has turned far too negative after the stock fell XX% since summer 2024. Yes Novo has lost share to $LLY but Johnny Madsen argues the selloff has gone too far: Novo has an attractive pipeline Its products have shown some stronger health data than Lillys Oral Wegovy expected in the U.S. in 2026 is a major opportunity His view: Novos portfolio is stronger than the market gives it credit for but the company"
X Link 2025-12-12T06:18Z 4893 followers, 2023 engagements

"$NVO has launched Ozempic in #India pricing at the low end to build scale ahead of generics. XXXX mg dose priced at $24/week Monthly prices range from 8800 to 11175 Sold in pen format (4 weekly doses per pen) India is a key battleground: Worlds 2nd-largest diabetes population Rapidly rising obesity rates Semaglutide patent expires in March 2026 The move aims to lock in market share before cheaper copies arrive as demand for GLP-1s continues to surge. Link to article: #StocksToWatch #Investing"
X Link 2025-12-12T08:24Z 4893 followers, 2206 engagements

"The European Medicines Agency has issued a positive opinion for a higher XXX mg dose of $NVO 's Wegovy. Key takeaways: Avg XXXX% weight loss at XX weeks X in X patients achieved 25%+ weight loss Majority of weight loss came from fat muscle function preserved Cardiovascular benefits maintained Final EU approval now pending. Novo has also submitted the XXX mg dose to regulators in the US UK and other markets. Link to announcement: #StocksInFocus #Investing"
X Link 2025-12-12T14:13Z 4893 followers, 2188 engagements

"Danish #stocks pulled back on Friday but finished the week higher. The C25 index slipped XXX% on the day yet still closed the week up 2.4%. $NVO edged up XXXX% on Friday and ended the week nearly X% higher"
X Link 2025-12-12T16:49Z 4893 followers, XXX engagements

"Ozempic now costs $24/week in India vs $249/week in the U.S. $NVO just launched Ozempic in India at a massive discount pricing the XXXX mg dose at 8800 per month. In the U.S. the same dose lists near $1000 before rebates. Why the gap Governments negotiate prices outside the U.S. Novo is prioritizing scale and access in emerging markets Locking in share ahead of Indias 2026 patent expiry Link to article: #stocks #Investing"
X Link 2025-12-12T18:55Z 4893 followers, 1019 engagements